Opko Health, Inc. (NASDAQ:OPK) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also recently issued reports on OPK. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. Jefferies Group LLC reiterated a “hold” rating and set a $6.50 target price (down previously from $6.80) on shares of Opko Health in a report on Thursday, August 10th. J P Morgan Chase & Co cut Opko Health from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. Finally, Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the stock a “buy” rating in a report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $13.97.

Shares of Opko Health (NASDAQ OPK) traded up $0.08 during trading hours on Friday, hitting $5.49. The stock had a trading volume of 5,750,000 shares, compared to its average volume of 4,004,709. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.50. Opko Health has a 1-year low of $5.35 and a 1-year high of $12.15.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.18% and a negative net margin of 9.45%. The firm had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The firm’s revenue for the quarter was down 11.6% compared to the same quarter last year. sell-side analysts forecast that Opko Health will post -0.2 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Opko Health, Inc. (OPK) Rating Lowered to Sell at BidaskClub” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/12/opko-health-inc-opk-rating-lowered-to-sell-at-bidaskclub.html.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 50,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were bought at an average cost of $5.96 per share, with a total value of $298,000.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,290,947.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the business’s stock in a transaction on Monday, October 30th. The stock was acquired at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the transaction, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,251,038 shares of company stock worth $5,581,640 over the last three months. 40.19% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in OPK. Financial Architects Inc raised its position in shares of Opko Health by 45.0% in the 2nd quarter. Financial Architects Inc now owns 15,460 shares of the company’s stock valued at $102,000 after purchasing an additional 4,800 shares in the last quarter. Blair William & Co. IL acquired a new position in shares of Opko Health in the 2nd quarter valued at approximately $112,000. Engineers Gate Manager LP acquired a new position in shares of Opko Health in the 2nd quarter valued at approximately $117,000. Crossmark Global Holdings Inc. acquired a new position in shares of Opko Health in the 3rd quarter valued at approximately $118,000. Finally, IFC Holdings Incorporated FL raised its position in shares of Opko Health by 16.5% during the 2nd quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the company’s stock valued at $119,000 after acquiring an additional 2,525 shares in the last quarter. 22.57% of the stock is currently owned by institutional investors.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.